MTORC1 and FGFR1 signaling in fibrolamellar hepatocellular carcinoma

Modern Pathology

Volumn 28, Issue 1, 2015, Pages 103-110

  Riehle, Kimberly J ^a,b,c   Yeh, Matthew M ^a   Yu, Jeannette J ^a,c   Kenerson, Heidi L ^b   Harris, William P ^a,b   Park, James O ^a,b   Yeung, Raymond S ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c SEATTLE CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR RECEPTOR 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; PROTEIN S6; FGFR1 PROTEIN, HUMAN; MECHANISTIC TARGET OF RAPAMYCIN COMPLEX 1; MULTIPROTEIN COMPLEX; TARGET OF RAPAMYCIN KINASE;

ADOLESCENT; ADULT; ARTICLE; CARCINOGENESIS; FEMALE; FIBROLAMELLAR CARCINOMA; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; MALE; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TISSUE MICROARRAY; METABOLISM; PATHOLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MALE; MULTIPROTEIN COMPLEXES; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 1; TISSUE ARRAY ANALYSIS; TOR SERINE-THREONINE KINASES; YOUNG ADULT;

EID: 84920649063     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2014.78     Document Type: Article

References (26)

1. Torbenson M. Fibrolamellar carcinoma: 2012 update. Scientifica 2012;2012:743790.
2. Ang CS, Kelley RK, Choti MA, et al. Clinicopathologic characteristics and survival outcomes of patients with fibrolamellar carcinoma: data from the fibrolamellar carcinoma consortium. Gastrointest Cancer Res 2013; 6:3-9.
3. Malouf GG, Job S, Paradis V, et al. Transcriptional profiling of pure fibrolamellar hepatocellular carcinoma reveals an endocrine signature. Hepatology 2014; 2014:27018.
4. Kannangai R, Vivekanandan P, Martinez-Murillo F, et al. Fibrolamellar carcinomas show overexpression of genes in the RAS, MAPK, PI3K, and xenobiotic degradation pathways. Human Pathol 2007;38:639-644.
5. Ruvinsky I, Sharon N, Lerer T, et al. Ribosomal protein S6 phosphorylation is a determinant of cell size and glucose homeostasis. Genes Dev 2005;19:2199-2211.
6. Thoreen CC, Chantranupong L, Keys HR, et al. A unifying model for mTORC1-mediated regulation of mRNA translation. Nature 2012;485:109-113.
7. Villanueva A, Chiang DY, Newell P, et al. Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology 2008;135:1972-1983; 83 e1-11.
8. Kenerson HL, Aicher LD, True LD, et al. Activated mammalian target of rapamycin pathway in the pathogenesis of tuberous sclerosis complex renal tumors. Cancer Res 2002;62:5645-5650.
9. Kenerson HL, Yeh MM, Kazami M, et al. Akt and mTORC1 have different roles during liver tumorigenesis in mice. Gastroenterology 2013;144:1055-1065.
10. Jaye M, Schlessinger J, Dionne CA. Fibroblast growth factor receptor tyrosine kinases: molecular analysis and signal transduction. Biochim Biophys Acta 1992; 1135:185-199.
11. Turner N, Grose R. Fibroblast growth factor signaling: from development to cancer. Nat Rev Cancer 2010; 10:116-129.
12. Giri D, Ropiquet F, Ittmann M. Alterations in expression of basic fibroblast growth factor (FGF) 2 and its receptor FGFR-1 in human prostate cancer. Clin Cancer Res 1999;5:1063-1071.
13. Welm BE, Freeman KW, Chen M, et al. Inducible dimerization of FGFR1: development of a mouse model to analyze progressive transformation of the mammary gland. J Cell Biol 2002;157:703-714.
14. Huang X, Yu C, Jin C, et al. Ectopic activity of fibroblast growth factor receptor 1 in hepatocytes accelerates hepatocarcinogenesis by driving proliferation and vascular endothelial growth factor-induced angiogenesis. Cancer Res 2006;66:1481-1490.
15. Kin M, Sata M, Ueno T, et al. Basic fibroblast growth factor regulates proliferation and motility of human hepatoma cells by an autocrine mechanism. J Hepatol 1997;27:677-687.
16. Cai MY, Tong ZT, Zheng F, et al. EZH2 protein: a promising immunomarker for the detection of hepatocellular carcinomas in liver needle biopsies. Gut 2011;60:967-976.
17. El-Serag HB. Hepatocellular carcinoma: recent trends in the United States. Gastroenterology 2004;127:S27-S34.
18. Stipa F, Yoon SS, Liau KH, et al. Outcome of patients with fibrolamellar hepatocellular carcinoma. Cancer 2006;106:1331-1338.
19. Weeda VB, Murawski M, McCabe AJ, et al. Fibrolamellar variant of hepatocellular carcinoma does not have a better survival than conventional hepatocellular carcinoma-results and treatment recommendations from the Childhood Liver Tumour Strategy Group (SIOPEL) experience. Eur J Cancer 2013;49: 2698-2704.
20. Eggert T, McGlynn KA, Duffy A, et al. Epidemiology of fibrolamellar hepatocellular carcinoma in the USA, 2000-10. Gut 2013;62:1667-1668.
21. Njei B. Long-term survival of fibrolamellar hepatocellular carcinoma versus conventional hepatocellular carcinoma: a US population-based study. J Clin Gastroenterol 2014;48:385-386.
22. Kaseb AO, Shama M, Sahin IH, et al. Prognostic indicators and treatment outcome in 94 cases of fibrolamellar hepatocellular carcinoma. Oncology 2013;85:197-203.
23. Ward SC, Huang J, Tickoo SK, et al. Fibrolamellar carcinoma of the liver exhibits immunohistochemical evidence of both hepatocyte and bile duct differentiation. Mod Pathol 2010;23:1180-1190.
24. Ross HM, Daniel HD, Vivekanandan P, et al. Fibrolamellar carcinomas are positive for CD68. Mod Pathol 2011;24:390-395.
25. Abdul-Al HM, Wang G, Makhlouf HR, et al. Fibrolamellar hepatocellular carcinoma: an immunohistochemical comparison with conventional hepatocellular carcinoma. Int J Surg Pathol 2010;18: 313-318.
26. Matter MS, Decaens T, Andersen JB, et al. Targeting the mTOR pathway in hepatocellular carcinoma: current state and future trends. J Hepatol 2014;60:855-865.